Literature DB >> 3359912

Sensitivity of Hemoccult test for large bowel cancer in high-risk subjects.

L Bertario1, P Spinelli, L Gennari, P Sala, P Pizzetti, A Severini, G Cozzi, M Bellomi, F Berrino.   

Abstract

From 1979 to 1982, 1233 symptom-free subjects at high risk for colon cancer because of family history and/or personal history of bowel neoplasia (cancer or adenomatous polyp) were examined with a guaiac test (Hemoccult II) for occult blood in stools. The test was positive (H+) in 98 subjects (7.9%). Endoscopy was subsequently performed on 86% of the H+ and on 64% of the H- subjects. Of 20 in invasive cancers found, 15 had been H+ [75.0%; 95% confidence interval (CI), 54.3-91.0%]. Of 96 patients with adenoma(s), 23 were H+ (24%; 95% CI, 16.0-33.0%). However, the sensitivity for adenomas was higher in patients with multiple adenomas or with a single adenoma measuring 2 cm or more in its largest diameter (37.5%; 95% CI, 21.8-54.7%). Of 699 subjects free of neoplastic lesions at endoscopy, 47 had been H+, ie, false positive (6.7%; 95% CI, 5.0-8.7%). Adjusting for differential compliance of H+ and H- subjects to endoscopy, a corrected estimate for sensitivity would be 69% for cancer and 19% for adenomas; the corrected estimate for the false-positive rate would be 5%.

Entities:  

Mesh:

Year:  1988        PMID: 3359912     DOI: 10.1007/bf01798365

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  16 in total

1.  Hemoccult detection of fecal occult blood quantitated by radioassay.

Authors:  J R Stroehlein; V F Fairbanks; D B McGill; V L Go
Journal:  Am J Dig Dis       Date:  1976-10

2.  Causes of delay in the diagnosis of cancer of the rectum and colon.

Authors:  R J Heald
Journal:  Practitioner       Date:  1977-09

3.  Sensitivity and reproducibility of chemical tests for fecal occult blood with an emphasis on false-positive reactions.

Authors:  J D Ostrow; C A Mulvaney; J R Hansell; R S Rhodes
Journal:  Am J Dig Dis       Date:  1973-11

4.  Current status of fecal occult blood testing in screening for colorectal cancer.

Authors:  S J Winawer; M Fleisher; M Baldwin; P Sherlock
Journal:  CA Cancer J Clin       Date:  1982 Mar-Apr       Impact factor: 508.702

5.  Sensitivity and specificity of the fecal occult blood test for colorectal neoplasia.

Authors:  S J Winawer; M Fleisher
Journal:  Gastroenterology       Date:  1982-05       Impact factor: 22.682

6.  Sensitivity of fecal occult blood testing for adenomas.

Authors:  S J Winawer; M Fleisher; P Sherlock
Journal:  Gastroenterology       Date:  1982-11       Impact factor: 22.682

7.  Relationship between patterns of bleeding and Hemoccult sensitivity in patients with colorectal cancers or adenomas.

Authors:  F A Macrae; D J St John
Journal:  Gastroenterology       Date:  1982-05       Impact factor: 22.682

8.  Immunochemical detection of fecal occult blood--the fecal smear punch-disc test: a new non-invasive screening test for colorectal cancer.

Authors:  C L Songster; G H Barrows; D D Jarrett
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

9.  Progress report on controlled trial of fecal occult blood testing for the detection of colorectal neoplasia.

Authors:  S J Winawer; M Andrews; B Flehinger; P Sherlock; D Schottenfeld; D G Miller
Journal:  Cancer       Date:  1980-06-15       Impact factor: 6.860

10.  Selective screening for colorectal tumors in the Tel-Aviv area: relevance of epidemiology and family history.

Authors:  P Rozen; Z Fireman; R Terdiman; S M Hellerstein; J Rattan; T Gilat
Journal:  Cancer       Date:  1981-02-15       Impact factor: 6.860

View more
  2 in total

1.  Effect of rehydration on guaiac-based faecal occult blood testing in colorectal cancer screening.

Authors:  G Castiglione; M Biagini; A Barchielli; G Grazzini; A Mazzotta; P Salvadori; L Scillone; S Ciatto
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

2.  Guaiac and immunochemical tests for faecal occult blood in colorectal cancer screening.

Authors:  G Castiglione; G Grazzini; S Ciatto
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.